<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01841073</url>
  </required_header>
  <id_info>
    <org_study_id>FermCarb</org_study_id>
    <nct_id>NCT01841073</nct_id>
  </id_info>
  <brief_title>Effect of Fermentable Carbohydrate on Glucose Homeostasis</brief_title>
  <acronym>FermCarb</acronym>
  <official_title>Effect of Fermentable Carbohydrate on Glucose Homeostasis and Weight Management in Subjects With Prediabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rise in the prevalence of type 2 diabetes is related to recent lifestyle changes leading&#xD;
      to a rise in obesity. Obesity is a risk factor for Impaired Glucose Tolerance (IGT) and&#xD;
      diabetes. A type of fibre - fermentable carbohydrate - may help prevent diabetes in&#xD;
      individuals with IGT by reducing appetite and food intake, and improving insulin sensitivity.&#xD;
      Although fermentable carbohydrate is not absorbed in the small intestine it is full fermented&#xD;
      by the colonic bacteria. The fermentation of this carbohydrate produces short chain fatty&#xD;
      acids which act on specific G protein coupled receptors (GPR41/43) in the intestine to&#xD;
      release GLP-1 and PYY. GLP-1 and PYY are hormones which act on appetite centres in the brain&#xD;
      to decrease appetite. GLP-1 incretin effects and possible effect of the beta cell will&#xD;
      increase insulin sensitivity. Short chain fatty acids also suppress the release of free fatty&#xD;
      acids from adipocytes. Lower levels of free fatty acids in insulin resistant subject's leads&#xD;
      to improved insulin sensitivity. This body of work will examine the effect of fermentable&#xD;
      carbohydrate on appetite, weight loss, blood glucose control which will give an indication of&#xD;
      the possibility of fermentable carbohydrate to prevent type 2 diabetes in this at-risk group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TITLE The Effect of Fermentable Carbohydrate on Weight Management and Glycaemic Control in&#xD;
      People at High Risk of Developing DMT2&#xD;
&#xD;
      AIMS To assess the effect of fermentable carbohydrate in subjects with pre-diabetes on:&#xD;
&#xD;
        1. Appetite regulation&#xD;
&#xD;
        2. Glucose homeostasis and B-cell function&#xD;
&#xD;
        3. Weight loss and changes in body composition&#xD;
&#xD;
        4. Weight loss maintenance&#xD;
&#xD;
        5. Markers of Oxidative Stress&#xD;
&#xD;
      DESIGN The investigators plan to conduct 3 investigations. Investigation 1 and 2 are&#xD;
      Randomised Crossover Control Trials of 14 days supplementation with 30g of inulin&#xD;
      (fermentable carbohydrate) or a cellulose (non fermentable carbohydrate) control to firstly&#xD;
      describe the physiology and mechanisms behind appetite regulation and glucose homeostasis.&#xD;
      Investigation 3 is a Randomised Control Parallel Study of weight loss followed by weight&#xD;
      maintenance to assess the efficacy of fermentable carbohydrate to decrease risk of T2DM.&#xD;
&#xD;
      POPULATION Overweight and obese men or women with pre-diabetes.&#xD;
&#xD;
      TREATMENT Participants in the treatment arm in all 3 investigations will consume inulin 3&#xD;
      times per day (total daily dose: 30g). Participants in the placebo arm in all 3&#xD;
      investigations will be taking cellulose 3 times a day (total daily dose: 30g).&#xD;
&#xD;
      DURATION Investigation 1 will last 16 weeks. Investigation 2 will last 18 weeks.&#xD;
      Investigation 3 will last 18 weeks.&#xD;
&#xD;
      BACKGROUND&#xD;
&#xD;
      Type 2 Diabetes (DMT2) is a major health concern in the UK, as it is worldwide. The increased&#xD;
      prevalence of DMT2 in the UK is closely linked with the increased prevalence of obesity, with&#xD;
      the risk for diabetes estimated to increase by 4.5-9 percent with every kilogram weight&#xD;
      gained (1). Pre-diabetes is also associated with an increase in body weight, and is a&#xD;
      critical step in the development of T2DM.&#xD;
&#xD;
      Having pre-diabetes also increases the risk for cardiovascular disease. It is thought this is&#xD;
      due to the hyperglycaemia and glycaemic variability seen in the pre-diabetic state. Both&#xD;
      hyperglycaemia and glycaemic variability are associated with oxidative stress. Oxidative&#xD;
      stress is postulated to cause endothelial damage which can lead to cardiovascular disease.&#xD;
      Reductions in hyperglycaemia and glycaemic variability may cause a reduction in oxidative&#xD;
      stress.&#xD;
&#xD;
      A number of gut hormones - released physiologically in response to food - have been shown to&#xD;
      powerfully inhibit human appetite and inhibit food intake and glucose homeostasis (2). Two of&#xD;
      these gut hormones, glucagon like peptide-1 (GLP-1) and peptide YY (PYY) are released from&#xD;
      the neuroendocrine L-cell in the colon, and have demonstrable appetite suppressive effects in&#xD;
      animals and humans (3-6). GLP-1 also improves glycaemic control by stimulating pancreatic&#xD;
      B-cells to secrete insulin in a glucose-dependent manner, inhibits glucagon release and&#xD;
      reduces hepatic glucose output (7-9). Long-term treatment with GLP-1 agonists has been shown&#xD;
      to cause significant weight loss in humans (10).&#xD;
&#xD;
      Work by ourselves and others in rodents have shown that dietary fermentable carbohydrates&#xD;
      (FCHOs) can significantly increase circulating PYY and GLP-1 levels while suppressing&#xD;
      appetite centres in the hypothalamus (11-12). This results in lower body fat and abdominal&#xD;
      fat with no overall effect on weight; however as abdominal fat is an important cardiovascular&#xD;
      risk factor in diabetes, this effect is likely to be favourable to health (13-14). In humans,&#xD;
      there are a number of short-term studies that report an increase in satiety following&#xD;
      consumption of FCHOs (15-16)and a year-long study of children consuming the FCHO inulin&#xD;
      showed significant weight loss compared to controls (17). FCHO has also been shown to&#xD;
      increase insulin sensitivity, reduce post-prandial blood glucose levels and enhance lipid&#xD;
      oxidation in overweight subjects with and without diabetes (18,19), effects that may be&#xD;
      mediated by the FCHO induced GLP-1 increase (GLP-1 was not measured in these studies). Even&#xD;
      short-term consumption of FCHO in healthy subjects has a similar effect on glycaemic control&#xD;
      (20).&#xD;
&#xD;
      STUDY DESIGN&#xD;
&#xD;
      Inulin will be used as the FCHO supplement in all 3 investigations. Inulin has no known&#xD;
      effect on the small bowel, being fully fermented in the large bowel. Inulin is therefore&#xD;
      ideally suited for the investigation of large bowel fermentation on human appetite, glycaemic&#xD;
      control and weight maintenance. Test&#xD;
&#xD;
      SCREENING PROCEDURE&#xD;
&#xD;
        1. Telephone screening will identify the members of this cohort who meet the initial&#xD;
           screening criteria of:&#xD;
&#xD;
           Adults over 18 years of age, Participants with no major metabolic disease - including&#xD;
           diabetes, no known/diagnosed gastrointestinal problem such as inflammatory bowel&#xD;
           disease, irritable bowel syndrome etc and no drug or alcohol abuse in the last 2 years.&#xD;
&#xD;
        2. At the Sir John McMichael Centre, participants will undergo the following:&#xD;
&#xD;
      An oral glucose tolerance test.&#xD;
&#xD;
      A blood sample of 30ml will be taken for full blood count, liver function tests,&#xD;
      electrolytes, thyroid function tests, HbA1c, and glucose.&#xD;
&#xD;
      Body weight and height will be recorded.&#xD;
&#xD;
      DETAILED PROTOCOL&#xD;
&#xD;
      APPETITE STUDY SESSIONS&#xD;
&#xD;
      Visit 1, 2, 3 &amp; 4 in Investigation 1.&#xD;
&#xD;
      Participants arrive fasted overnight (10 hour fast). After explanation of the procedures and&#xD;
      confirmation that the participant is happy to proceed, body weight is recorded.&#xD;
&#xD;
      A cannula is inserted in a forearm vein facilitating blood sampling throughout the day. Two&#xD;
      baseline blood samples are withdrawn. Visual analogue scales (VAS) are completed every time a&#xD;
      blood sample is drawn. The sampling scheme is presented below. A total of 80ml of blood will&#xD;
      taken during investigation 1 appetite study days, and a total of 115ml be withdrawn during&#xD;
      each appetite study visit in investigation 3. Visual Analogue scales to assess appetite will&#xD;
      be completed each time a blood sample is taken. The Visual Analogue Scale questions include:&#xD;
      &quot;How full do you feel right now?&quot; and &quot;How hungry do you feel right now?&quot; and &quot;How much could&#xD;
      you eat right now?&quot;. They will answer by making a vertical mark on a ten centimetre line&#xD;
      anchored with the terms &quot;not at all&quot; and &quot;extremely&quot;. Similarly, side-effects such as nausea,&#xD;
      sickness, flatulence, bloating, diarrhoea, and general well-being will be assessed.&#xD;
&#xD;
      At time 0, breakfast is served and participants will have 20 minutes to consume the meal.&#xD;
      Lunch is served at 240 minutes, and the meal test is served at 440 minutes after the last&#xD;
      blood sample is taken.&#xD;
&#xD;
      During the study session, participants will be asked to minimize physical activity. Water is&#xD;
      allowed freely, though participants will be requested not to drink less than 10 minutes prior&#xD;
      to a blood sample and VAS completion. At 440 minutes, a pre-weighed meal is served. The meal&#xD;
      is served in excess and participants are asked to eat until comfortably full. A jug of water&#xD;
      is served with the meal and the water intake will also be recorded.&#xD;
&#xD;
      In investigation 3, the study sessions will be shorter, consisting of a breakfast and a meal&#xD;
      test at lunch.&#xD;
&#xD;
      ONE TO ONE DIETARY COUNSELLING&#xD;
&#xD;
      In Investigation 3, all participants will receive dietary counselling at weeks 1, 2, 4, and&#xD;
      7. The instruction given to the participants will be individualised based on current weight&#xD;
      and energy requirements, consistent with the usual package of care that would be offered&#xD;
      within a dietitian clinic. The participants will be instructed to aim for 5% weight loss over&#xD;
      9 weeks.&#xD;
&#xD;
      SUPPLEMENTATION UNDER FREE-LIVING CONDITIONS&#xD;
&#xD;
      The supplement will be provided in sachets (containing 10g portions). During the run-in&#xD;
      period the daily intake will gradually be increased to 30g per day over 4 weeks. During this&#xD;
      run-in period the investigators will contact the participants via e-mail or telephone twice&#xD;
      to ensure the fibre supplementation has no un-toward side-effects and ensure that&#xD;
      instructions are followed and answer any questions the participants may have. The subjects&#xD;
      then take 30g a day until the end of the study (at 6 weeks for investigation 1 or 18 weeks in&#xD;
      investigation 3).&#xD;
&#xD;
      WASHOUT PERIOD&#xD;
&#xD;
      In investigations 1 and 2 there will be a wash out period of 4 weeks before the subject&#xD;
      crosses over the the alternate supplementation.&#xD;
&#xD;
      DIETARY RECORDS, APPETITE AND SIDE-EFFECTS&#xD;
&#xD;
      A 3-day dietary record is to be completed for the 3 days preceding visits 1, 2 and 3 during&#xD;
      Investigation 1, and visits 1, 6 and 7 during Investigation 3. On the same days, appetite&#xD;
      sensation and side-effects will be assessed using visual analogue scales. The Visual Analogue&#xD;
      Scale questions include: &quot;How full did you feel after eating meals today?&quot; and &quot;How hungry&#xD;
      did you feel between meals today?&quot;. They will answer by making a vertical mark on a ten&#xD;
      centimetre line anchored with the terms &quot;not at all&quot; and &quot;extremely&quot;. Similarly, side-effects&#xD;
      such as nausea, sickness, flatulence, bloating, diarrhoea, and general well-being will be&#xD;
      assessed.&#xD;
&#xD;
      METHODS FOR ASSESSING INSULIN AND GLUCOSE HOMOSTASIS MEAL TOLERANCE TEST Participant will&#xD;
      attend the clinical investigation unit a 12 hour fast. A cannula will be placed in their&#xD;
      forearm. Three fasting blood samples will be taken (-30, -15 and 0). A standard test meal of&#xD;
      one Kellogg's breakfast bar and an Ensure Plus will be given. Blood will be taken at 0, 5,&#xD;
      10, 15, 20, 30, 45, 60, 90, 120, 150, 180 amd 240 mins. This will be used to calculate&#xD;
      Glucose profile, basal insulin response, dynamic phase insulin, static phase insulin&#xD;
      sensitivity, DI=Dynamic phase insulin X Static phase insulin, GIP and GLP-1 response.&#xD;
&#xD;
      Free living glucose monitoring: Medtronic iPro Continuous Glucose Monitor will be used to&#xD;
      assess 5-day continuous glucose monitoring. 5-day continuous glucose monitoring to assess&#xD;
      &quot;free living&quot; glucose homeostasis. This interstitial fluid glucose data will be analysed for&#xD;
      mean glucose and glycaemic variability measures including Mean Amplitude Glycaemic Excursions&#xD;
      (MAGE), Continuous Overlapping Net Glycaemic Action (CONGA) and risk indices such as Low&#xD;
      Blood Glucose Index (LBGI), High Blood Glucose Index (HBGI) and average daily risk ratio&#xD;
      (ADRR). For the participant this will mean having a small plastic cannula place in the&#xD;
      subcutaneous tissue in their abdomen. The participants will also be required to take 3&#xD;
      finger-prick glucose measurements on 4 successive days while wearing the CGM.&#xD;
&#xD;
      WHOLE BODY MRI SCANNING In investigation 3, whole body anatomical MR scanning will be&#xD;
      performed to determine total and regional fat volumes, and magnetic resonance spectroscopy&#xD;
      (MRS) performed to measure lipid content in the internal organs, such as liver (IHCL) and&#xD;
      muscles (IMCL), such as soleus and tibialis.&#xD;
&#xD;
      Participants will attend the Robert Steiner MRI unit at Hammersmith Hospital after a 10h&#xD;
      overnight fast. The study visit will last 1 hour. Participants are asked to refrain from&#xD;
      strenuous exercise and drinking alcohol the day before each visit.&#xD;
&#xD;
      Firstly subjects will complete a metal check form. Next subjects will change into hospital&#xD;
      clothes and be asked to lie on the trolley in the scanner. Subjects lie supine or prone in&#xD;
      the scanner and are automatically moved through the scanner. While in the scanner&#xD;
      participants will have access to a buzzer to sound an alarm, and will be able to hear and&#xD;
      respond to instructions from the scanning console. Subjects will be in the MRI scanner for up&#xD;
      to 1 hour. Scanning will be performed on either the Philips 3.0 Tesla or Philips 1.5 Tesla MR&#xD;
      scanners in the Robert Steiner MRI Unit at the Hammersmith Hospital. None of the magnetic&#xD;
      resonance imaging techniques to be used employs ionising radiation or intravenous contrast&#xD;
      agents. Participants will also have their weight, height, waist and hip circumference&#xD;
      recorded with a tape measure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycaemic Control</measure>
    <time_frame>9 weeks</time_frame>
    <description>An oral glucose tolerance test (OGTT) using 75 g of glucose was performed to clarify glycaemic status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Food Intake in Gram at 9 Weeks</measure>
    <time_frame>9 weeks</time_frame>
    <description>Food intake following intervention over 9 weeks compared to baseline and between the two group</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage Change in Body Weight</measure>
    <time_frame>9 weeks</time_frame>
    <description>Change in body weight over 9 week intervention</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Prediabetes</condition>
  <arm_group>
    <arm_group_label>Inulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will take 10g inulin for 2 weeks, 20g of inulin for the next 2 weeks and then 30g for the remainder of the investigations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cellulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will take 10g cellulose a day for 2 weeks, followed by 20g a day for 2 weeks, then 30g a day for the rest of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inulin</intervention_name>
    <description>Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.</description>
    <arm_group_label>Inulin</arm_group_label>
    <other_name>Synergy1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cellulose</intervention_name>
    <description>Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.</description>
    <arm_group_label>Cellulose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inulin</intervention_name>
    <description>Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.</description>
    <arm_group_label>Inulin</arm_group_label>
    <other_name>Synergy1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cellulose</intervention_name>
    <description>Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.</description>
    <arm_group_label>Cellulose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inulin</intervention_name>
    <description>Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.&#xD;
Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study.</description>
    <arm_group_label>Inulin</arm_group_label>
    <other_name>Synergy1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cellulose</intervention_name>
    <description>Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.&#xD;
Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study.</description>
    <arm_group_label>Cellulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Investigation 1 and 3: An oral glucose tolerance test diagnostic of impaired glucose&#xD;
             tolerance as defined by the WHO as a fasting plasma glucose&lt;7.0mmol/l and a 2-h plasma&#xD;
             glucose ≥7.8 and &lt;11.1mmol/l and/or impaired fasting glucose, defined by the American&#xD;
             Diabetes Association as a fasting plasma glucose of &gt;5.6 and &lt;6.9mmol/L.&#xD;
&#xD;
          -  Investigation 2: An oral glucose tolerance test diagnostic of impaired glucose&#xD;
             tolerance as defined by the WHO as a fasting plasma glucose&lt;7.0mmol/l and a 2-h plasma&#xD;
             glucose ≥7.8 and &lt;11.1mmol/l. For investigation 2, people with only IFG will be&#xD;
             excluded.&#xD;
&#xD;
          -  All investigations:&#xD;
&#xD;
          -  Adults over 18 years of age&#xD;
&#xD;
          -  Males and Females with a BMI between 25-35 kg/m2. The BMI range of between 25-35Kg/m2&#xD;
             has been chosen as this is the range that the majority of overweight people fall into&#xD;
             (1). At this level of overweight and obesity there is an increase in the risk of type&#xD;
             2 diabetes. Above 40 kg/m2 there appears to be decreased success with lifestyle&#xD;
             advice.&#xD;
&#xD;
          -  The volunteers should have given full written consent.&#xD;
&#xD;
          -  Have had a stable body weight for the last 6 months with no more than a 5% change in&#xD;
             body weight over 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults less than 18 years of age.&#xD;
&#xD;
          -  Volunteers with a major metabolic disease - including diabetes.&#xD;
&#xD;
          -  A normal oral glucose tolerance test or that diagnostic of diabetes by the WHO&#xD;
             criteria.&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
&#xD;
          -  Males and Females with a BMI less than 25kg/m2 or greater than 35kg/m2&#xD;
&#xD;
          -  Volunteers unable to give informed consent for themselves.&#xD;
&#xD;
          -  Has lost or gained 5% of their normal body weight in the last 6 months.&#xD;
&#xD;
          -  Has a known/diagnosed gastrointestinal problem such as inflammatory bowel disease,&#xD;
             irritable bowel syndrome etc&#xD;
&#xD;
          -  Failure of the medical examination for inclusion into the study&#xD;
&#xD;
          -  Those with anaemia (Hb &lt;10g/l)&#xD;
&#xD;
          -  Drug or alcohol abuse in the last 2 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Frost, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imperial College London</name>
      <address>
        <city>London</city>
        <zip>W11 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Guess ND, Dornhorst A, Oliver N, Frost GS. A Randomised Crossover Trial: The Effect of Inulin on Glucose Homeostasis in Subtypes of Prediabetes. Ann Nutr Metab. 2016;68(1):26-34. doi: 10.1159/000441626. Epub 2015 Nov 17.</citation>
    <PMID>26571012</PMID>
  </results_reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>April 5, 2013</study_first_submitted>
  <study_first_submitted_qc>April 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2013</study_first_posted>
  <results_first_submitted>October 9, 2019</results_first_submitted>
  <results_first_submitted_qc>October 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2019</results_first_posted>
  <last_update_submitted>November 11, 2019</last_update_submitted>
  <last_update_submitted_qc>November 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prediabetes</keyword>
  <keyword>Fermentable carbohydrate</keyword>
  <keyword>Appetite</keyword>
  <keyword>Glucose homeostasis</keyword>
  <keyword>Weight management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Inulin</title>
          <description>Inulin intervention</description>
        </group>
        <group group_id="P2">
          <title>Cellulose</title>
          <description>Cellulose intervention</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inulin</title>
          <description>Participant received inulin</description>
        </group>
        <group group_id="B2">
          <title>Cellulose</title>
          <description>Participants received cellulose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.2" spread="12"/>
                    <measurement group_id="B2" value="59.7" spread="8.9"/>
                    <measurement group_id="B3" value="58.95" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88.2" spread="14"/>
                    <measurement group_id="B2" value="83.4" spread="19.7"/>
                    <measurement group_id="B3" value="85.8" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.8" spread="4.1"/>
                    <measurement group_id="B2" value="30" spread="2.3"/>
                    <measurement group_id="B3" value="30.4" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Haemoglobin A1c</title>
          <units>mmol/mol</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="20"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.9" spread="0.1"/>
                    <measurement group_id="B2" value="5.7" spread="0.1"/>
                    <measurement group_id="B3" value="5.8" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glycaemic Control</title>
        <description>An oral glucose tolerance test (OGTT) using 75 g of glucose was performed to clarify glycaemic status.</description>
        <time_frame>9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inulin</title>
            <description>Received Inulin intervention</description>
          </group>
          <group group_id="O2">
            <title>Cellulose</title>
            <description>Received Cellulose intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Glycaemic Control</title>
          <description>An oral glucose tolerance test (OGTT) using 75 g of glucose was performed to clarify glycaemic status.</description>
          <units>mmol//l</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="0.17"/>
                    <measurement group_id="O2" value="0.44" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>p-value was calculated, and is not attempting to indicate the threshold for statistical significance</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Food Intake in Gram at 9 Weeks</title>
        <description>Food intake following intervention over 9 weeks compared to baseline and between the two group</description>
        <time_frame>9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inulin</title>
            <description>Inulin intervention</description>
          </group>
          <group group_id="O2">
            <title>Cellulose</title>
            <description>Cellulose intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Food Intake in Gram at 9 Weeks</title>
          <description>Food intake following intervention over 9 weeks compared to baseline and between the two group</description>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-127" spread="45.4"/>
                    <measurement group_id="O2" value="-0.47" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage Change in Body Weight</title>
        <description>Change in body weight over 9 week intervention</description>
        <time_frame>9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Inulin</title>
            <description>Received Inulin intervention</description>
          </group>
          <group group_id="O2">
            <title>Cellulose</title>
            <description>Received Cellulose intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Body Weight</title>
          <description>Change in body weight over 9 week intervention</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="0.1"/>
                    <measurement group_id="O2" value="-4.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Inulin</title>
          <description>Received Inulin intervention</description>
        </group>
        <group group_id="E2">
          <title>Cellulose</title>
          <description>Received Cellulose intervention</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof Gary Frost</name_or_title>
      <organization>Imperial College London</organization>
      <phone>+44 (0)20 7594 0959</phone>
      <email>g.frost@imperial.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

